Press "Enter" to skip to content

Controversial Alzheimer’s drug administered to a patient for the first time

While Aduhelm was approved based on evidence that it could reduce brain plaque in Alzheimer’s disease, scientists objected that the drug was only tested in early-stage Alzheimer’s patients.

While there were criticisms of the high price of this treatment, which is expected to cost approximately $ 60,000, three scientists in a panel that advised the FDA recently resigned after the drug was approved.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *